Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance and Announces Board Resignation
Sun Pharmaceutical Industries Ltd · Outcome · 13 Oct 2026, 1:26 am
Sun Pharma Approves Up to ₹10,000 Crore NCD Issuance and Announces Board Resignation Sun Pharmaceutical Industries' Board approved the issuance of listed, rated, unsecured, redeemable Non-Convertible Debentures (NCDs) on a private placement basis for an aggregate amount not exceeding INR 10,000 Crore, in one or more tranches. The Board also authorized its Finance Committee to determine tranche-specific terms, issuance, allocation, and allotment. Separately, Non-Executive Independent Director Gautam Doshi resigned with immediate effect on 12th Oct'26, citing personal commitments, consequently stepping down from all Board committees and subsidiary directorships with no other material reasons reported.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
